Metastasis-associated protein 1: a druggable target in cancer treatment.

Metastasis-associated genes (MTAs) play a critical role in cancer invasion and metastasis. MTAs make up a rapidly expanding gene family with three known genes: MTA1, MTA2, and MTA3. In particular, MTA1 acts as a transcriptional regulator that induces epithelial-mesenchymal transition (EMT) in various solid tumors. It is the first gene discovered in mice, was identified in 1994 [ 1 ]. In humans, the MTA1 gene consists of 21 sections and can produce 20 different transcripts through alternative splicing. These transcripts encode proteins that play crucial roles in regulating gene expression and are particularly significant in the development and spread of various cancers, including breast, liver, colon, pancreas, prostate, blood, esophageal, and gastrointestinal cancers. The MTA1 protein, with 715 amino acids, is longer than MTA2 and MTA3, which contain 668 and 594 amino acids, respectively [ 1 ]. MTA proteins are integral components of the NuRD complex (nuclear remodeling and deacetylation complex) and are believed to modulate transcription by influencing chromatin remodeling [ 2 ]. MTA1, in particular, is strongly associated with the aggressiveness of several cancers and is considered a potential target for cancer therapy [ 3 ]. Additionally, MTA1 exhibits various functions independent of the NuRD complex, contributing to cancer progression and metastasis through its interaction with genes and proteins involved in processes such as transformation, growth, invasion, survival, and resistance to therapy. Ongoing research on MTA1 aims to better understand its crucial roles in cancer development, metabolism, and inflammation. MTAs are a type of gene that is involved in the spread of cancer. MTA1 is especially important in many types of cancers, and scientists are studying it to find new ways to treat cancer. It is also involved in other processes in the body, and understanding how it works could help us find new treatments for different diseases.

Pterostilbene (PTER) has the ability to inhibit MTA1 expression and retard tumor growth. PTER downregulates MTA1, decreases the activity and effective concentration of HDAC1, which destabilizes the MTA1/HDAC complex and increases the acetylation and activation of phosphatase and tensin homolog (PTEN) [ 23 ]. This inverse relationship between MTA1 and PTEN is significant, as in aggressive PCa, nuclear MTA1 interacts with acetylated PTEN and inhibits its tumor-suppressive functions. Importantly, resveratrol can reactivate PTEN by reversing the negative effect of MTA1/HDAC-mediated deacetylation [ 24 ]. A study found that PTER exhibits inhibitory effects in breast, lung, prostate, and esophageal cancers, but less is reported regarding its potential for treating liver cancer. PTER is a type of stilbene compound extracted from sources like grapes, peanuts, and wine [ 23 ]. Gnetin C, a resveratrol dimer and dietary compound found in the melinjo plant, is more potent than resveratrol and PTER in exerting anticancer effects in PCa. This potency is, at least in part, due to Gnetin C’s inhibition of the cancer-promoting cooperation between MTA1 and ETS proto-oncogene 2 (ETS2). Our data indicate that Gnetin C induces cytotoxicity, cell death, and reduced metastatic ability in PCa cells through MTA1-mediated mechanisms. While the effects of Gnetin C are primarily mediated through MTA1 and the MTA1-dependent inhibition of ETS2, Gnetin C also demonstrated MTA1-independent targeting of ETS2. Therefore, Gnetin C’s dual inhibition of the MTA1/ETS2 axis may provide more robust anticancer effects in PCa. Collectively, our findings suggest the potential of Gnetin C as an MTA1/ETS2-targeted chemopreventive and possibly therapeutic strategy for PCa [ 25 ]. Additionally, other compounds such as isoflavone, gingerol, citronellal, and asiatic acid could be potent MTA inhibitors to prevent cancer metastasis. Furthermore, several structural analogs from DrugBank, including Tramadol, Nabumetone, DGLA, and Hydrocortisone, may be effective and show potency in inhibiting cancer progression in the early stage ( Fig. 5 ) [ 25 ].

Inhibition of MTA1 is a crucial area of research in the field of cancer biology. Metastasis is the process of cancer cells spreading from the primary tumor site to other parts of the body, leading to the formation of secondary tumors. Therefore, inhibiting MTA1 can potentially prevent or slow down the spread of cancer, making it an attractive target for therapeutic interventions. One approach to inhibiting MTA1 is through the use of small molecule inhibitors. Small molecules are organic compounds that can interact with specific proteins and interfere with their function. Several studies have identified small molecules that can selectively bind to MTA1 and inhibit its activity. These inhibitors can block the interaction between MTA1 and other proteins involved in the metastatic process, thereby reducing the ability of cancer cells to invade and migrate. Inhibition of MTA1 by small molecules has shown promising results in preclinical studies, highlighting its potential as a therapeutic strategy. Another way to inhibit MTA1 is through the modulation of its gene expression. MTA1 expression is regulated by various signaling pathways and transcription factors that control the activity of its gene. Researchers have identified several molecules that can target these pathways and transcription factors to down regulate MTA1 expression. By reducing the production of MTA1 protein, the metastatic potential of cancer cells can be attenuated. This approach offers a more indirect method of inhibiting MTA1 but can still be effective in preventing cancer metastasis. In conclusion, MTA1 represents an exciting druggable target in the field of cancer research. Its association with cancer metastasis and over expression in various types of cancer make it an attractive candidate for therapeutic intervention. Further research and clinical trials are needed to fully understand the therapeutic potential of MTA1 and translate these findings into effective treatments for cancer patients.